Stock Report

Vivanza Biosciences Q3FY22 consolidated loss at Rs. 4.76 lakhs



Posted On : 2022-02-11 11:49:34( TIMEZONE : IST )

Vivanza Biosciences Q3FY22 consolidated loss at Rs. 4.76 lakhs

has reported Consolidated financial results for the period ended December 31, 2021.

Financial Results (Q3 FY2022) - QoQ Comparison

The company has reported total income of Rs. 1.5422 crores during the period ended December 31, 2021 as compared to Rs. 2.8372 crores during the period ended September 30, 2021.

The company has posted net profit / (loss) of Rs. -0.0476 crores for the period ended December 31, 2021 as against net profit / (loss) of Rs. 0.2588 crores for the period ended September 30, 2021.

The company has reported EPS of Rs. -0.12 for the period ended December 31, 2021 as compared to Rs. 0.65 for the period ended September 30, 2021.

Financials Q3 FY2022 Q2 FY2022 % Change
Total Income ₹ 1.5422 crs ₹2.8372 crs Up Tick / Down Tick-45.64%
Net Profit ₹-0.0476 crs ₹0.2588 crs Up Tick / Down Tick-118.39%
EPS ₹-0.12 ₹0.65 Up Tick / Down Tick-118.46%

Financial Results (Q3 FY2022) - YoY Comparison

The company has reported total income of Rs. 1.5422 crores during the period ended December 31, 2021 as compared to Rs.4.1206 crores during the period ended December 31, 2020.

The company has posted net profit / (loss) of Rs.-0.0476 crores for the period ended December 31, 2021 as against net profit / (loss) of Rs.0.1657 crores for the period ended December 31, 2020.

The company has reported EPS of Rs.-0.12 for the period ended December 31, 2021 as compared to Rs.0.41 for the period ended December 31, 2020.

Financials Q3 FY2022 Q3 FY2021 % Change
Total Income ₹ 1.5422 crs ₹4.1206 crs Up Tick / Down Tick-62.57%
Net Profit ₹-0.0476 crs ₹0.1657 crs Up Tick / Down Tick-128.73%
EPS ₹-0.12 ₹0.41 Up Tick / Down Tick-129.27%

Financial Results (9 Months Ended FY2022) - YoY Comparison

The company has reported total income of Rs.5.0890 crores during the 9 Months period ended December 31, 2021 as compared to Rs.3.8144 crores during the 9 Months period ended December 31, 2020.

The company has posted net profit / (loss) of Rs.0.5330 crores for the 9 Months period ended December 31, 2021 as against net profit / (loss) of Rs.0.09 crores for the 9 Months period ended December 31, 2020.

The company has reported EPS of Rs.1.33 for the 9 Months period ended December 31, 2021 as compared to Rs.0.23 for the 9 Months period ended December 31, 2020.

Financials 9 Months Ended FY2022 9 Months Ended FY2021 % Change
Total Income ₹5.0890 crs ₹3.8144 crs Up Tick / Down Tick33.42%
Net Profit ₹0.5330 crs ₹0.09 crs Up Tick / Down Tick492.22%
EPS ₹1.33 ₹0.23 Up Tick / Down Tick478.26%

Source : Equity Bulls

Keywords

VivanzaBiosciences Q3FY22 9MFY22 ResultUpdate VSSL